Figure 3.

Progression of anti-glutamic acid decarboxylase (GAD) antibody levels over time (months of treatment). Treatment with sitagliptin and vitamin D3 started at 0 month. Point A: interruption of insulin glargine and lispro (patient #1), point B: interruption of insulin glargine (patient #2). Anti-GAD antibodies were measured with ELISA (reference value: <10 IU/mL). All tests were performed in the same clinical laboratory (Carlos Chagas, Cuiabá, Brazil).